GENERAL FLUIDICS CORPORATION

General Fluidics Corporation is a company dedicated to improving global health by making high-quality blood diagnostics more accessible. They accomplish this through their Axess point-of-care testing platform, which brings the quality and range of tests typically found in a reference laboratory directly to the point of care. This platform seamlessly integrates three "gold standard" analytical technologies to provide full hematology, clinical chemistry, and immunoassay test menus, offering a comprehensive diagnostic solution.

The Axess platform is designed to be an end-to-end solution, streamlining the testing workflow from sample collection to delivery and minimizing the burden on clinical staff. It boasts a low-cost, flexible, and high-quality testing approach, making it ideal for a wide range of acute and ambulatory care testing needs. General Fluidics emphasizes the importance of accessibility, affordability, and convenience in healthcare, aiming to deliver the best care at the lowest cost with reduced barriers, regardless of location.

General Fluidics Corporation aims to improve global health by making high-quality blood diagnostics more accessible. Their Axess point-of-care testing platform brings together patients, clinicians, and trusted diagnostic information, creating a new category of blood testing technology that delivers the quality of a reference laboratory directly to the point of care.

General Fluidics promotes a culture focused on innovation, collaboration, and a shared commitment to improving healthcare globally. They prioritize high-quality diagnostic testing, seeking to make it more accessible for patients and providers alike. Their "Point of Care Laboratory" approach emphasizes convenient access to comprehensive testing solutions, showcasing a culture dedicated to improving patient outcomes and simplifying workflows.